|
|
(21 intermediate revisions by 2 users not shown) |
Line 1: |
Line 1: |
| __NOEDITSECTION____NOTOC__
| |
| {{Meningitis}}
| |
|
| |
|
| {{CMG}}; {{AE}} {{CZ}}, {{SS}}
| |
|
| |
|
| ==Empiric Therapy==
| | {|style="width:10%;" border=2 |
| | | | {{Sandbox/v31}} |
| <BIG><BIG>'''Community-Acquired Meningitis'''</BIG></BIG>
| |
| <div class="mw-customtoggle-table01" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Newborn, Age <1 Week'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table01"
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;" | |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Newborn, Age <1 Week}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 100—150 mg/kg/day IV q8—12h'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 50 mg/kg IV q8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q12h'''''
| |
| |}
| |
| |}
| |
| <div class="mw-customtoggle-table02" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Newborn, Age 1—4 Weeks'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table02"
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
| |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Newborn, Age 1—4 Weeks}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 150—200 mg/kg/day IV q6—8h'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 200 mg/kg/day IV q6—8h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸'''''[[Tobramycin]]2.5 mg/kg IV q8h''''' <BR> OR <BR> ▸ '''''[[Amikacin]] 10 mg/kg IV q8h'''''
| |
| |}
| |
| |}
| |
| <div class="mw-customtoggle-table03" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Infant & Children'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table03"
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
| |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Infant & Children}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 15 mg/kg IV q6h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 225—300 mg/kg/day IV q6–8h''''' <BR>''OR''<BR>▸'''''[[Ceftriaxone]] 80—100 mg/kg/day IV q12–24h'''''
| |
| |-
| |
| |}
| |
| |}
| |
| <div class="mw-customtoggle-table04" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Adult, Age <50 Years'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table04"
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
| |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age <50 Years}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h''''' <BR> to achieve serum trough concentrations of 15–20 μg/mL
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR>▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |-
| |
| | <SMALL><sup>†</sup> Add '''''[[Ampicillin]] 2 g IV q4h''''' ('''''50 mg/kg IV q6h''''' for children) if meningitis caused by ''[[Listeria monocytogenes]]'' is also suspected.</SMALL>
| |
| | |
| |-
| |
| |}
| |
| |}
| |
| <div class="mw-customtoggle-table05" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Adult, Age >50 Years'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table05"
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
| |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult, Age >50 Years}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR>▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |-
| |
| |}
| |
| |}
| |
| <div class="mw-customtoggle-table06" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Immunocompromised'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table06"
| |
| |- | |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
| |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Immunocompromised}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30–60 mg/kg/day IV q8–12h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 g IV q4h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 2 g IV q8h''''' <BR> ''OR'' <BR> ▸ '''''[[Meropenem]] 2 g IV q8h'''''
| |
| |-
| |
| |}
| |
| |}
| |
| <div class="mw-customtoggle-table07" style="width: 300px; background: #F8F8FF; border: 2px solid #696969">  ▸ <font color="#1f4099">'''Recurrent'''</font></div>
| |
| {| class="wikitable mw-collapsible mw-collapsed" id="mw-customcollapsible-table07"
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
| |
| ! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Recurrent}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR>▸'''''[[Ceftriaxone]] 2 g IV q12h'''''
| |
| |}
| |
| |} | | |} |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| <div class="mw-collapsible mw-collapsed">
| |
|
| |
| =====Healthcare-Associated Meningitis=====
| |
|
| |
| <div class="mw-collapsible-content">
| |
|
| |
| {|
| |
| |-
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
| |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Basilar Skull Fracture}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 8–12 g/day IV q4–6h'''''<BR> ''OR'' <BR> ▸'''''[[Ceftriaxone]] 2 g IV q12h'''''<BR><BR><BR>
| |
| |}
| |
| | valign=top |
| |
| {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:32em" cellpadding="0" cellspacing="0";
| |
| ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Head Trauma; Post-Neurosurgery}}''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 30—60 mg/kg/day IV q8–12h'''''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS''
| |
| |-
| |
| | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8 h'''''<BR>''OR''<BR>▸ '''''[[Cefepime]] 2 g IV q8h'''''<BR>''OR''<BR>▸ '''''[[Meropenem]] 2 g IV q8h'''''
| |
| |}
| |
| |}
| |
|
| |
| <SMALL>Adapted from ''Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.''</SMALL><ref name="van de Beek-2012">{{Cite journal | last1 = van de Beek | first1 = D. | last2 = Brouwer | first2 = MC. | last3 = Thwaites | first3 = GE. | last4 = Tunkel | first4 = AR. | title = Advances in treatment of bacterial meningitis. | journal = Lancet | volume = 380 | issue = 9854 | pages = 1693-702 | month = Nov | year = 2012 | doi = 10.1016/S0140-6736(12)61186-6 | PMID = 23141618 }}</ref>
| |
|
| |
| </div></div>
| |
|
| |
|
| |
| ==References==
| |
| {{reflist|2}}
| |
|
| |
| [[Category:Needs overview]]
| |
| [[Category:Primary care]]
| |
| [[Category:Disease]]
| |
| [[Category:Infectious disease]]
| |
| [[Category:Neurology]]
| |
| [[Category:Emergency medicine]]
| |
| [[Category:Diseases involving the fasciae]]
| |
| [[Category:Inflammations]]
| |
| [[Category:Neurological disorders]]
| |
|
| |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |